Medicines Industry Liaison Group

The Medicines Industry Liaison Group (MLG) provides a forum for engagement, discussion, and constructive challenge between the Medicines and Healthcare products Regulatory Agency and the medicines industry to support the Agency in achieving its strategic aims.

Role of the group

Terms of reference

To ensure industry stakeholder participation in the development and evaluation of MHRA regulatory policy by meeting on a quarterly basis to:

  • share views and consult on existing and planned regulatory matters (legislative and non-legislative) that affect the medicines industry and make recommendations for regulatory requirements which are proportionate to the risk and benefit to public health;
  • provide an opportunity for industry to raise any issues / concerns and hold the agency to account for delivery against commitments;
  • consider the impact of process and information technology changes in MHRA on business;
  • progress burden reduction work, including compliance with Government Business Impact Target;
  • progress work arising from the annual cross- trade meeting; and
  • have a role in the review of MHRA guidance


Chair: MHRA Director of Policy


MHRA members are drawn from:

  • Communications
  • Inspection, Enforcement and Standards
  • Licensing
  • Operations and Finance
  • Policy
  • Vigilance Risk Management of Medicines


Department of Health and Social Care (to be sent papers and invited to meetings as needed).

Industry members

Industry is represented by:

  • ABPI (Association of the British Pharmaceutical Industry)
  • BAHM (British Association of Homeopathic Manufacturers)
  • BGMA (British Generic Manufacturers Association)
  • BIA (BioIndustry Association)
  • CCA (Company Chemists’ Association)
  • EMIG (Ethical Medicines Industry Group)
  • Herbal Forum
  • NPA (National Pharmacy Association)
  • PAGB (Proprietary Association of Great Britain)


Policy Division


For further information please contact